ArticlePharmaceuticals (Basel, Switzerland)2022

Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.

Katarzyna Kotfis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.